Impact of metabolic unhealthiness and its changes on the risk of erosive esophagitis: a cohort study

Documenti analoghi

• Association of metabolic dysfunction‐associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study
  di: Masahiro Sogabe, et al.
  Pubblicazione: (2024)
• The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double‐blind, multicenter study
  di: Qianjun Zhuang, et al.
  Pubblicazione: (2024)
• Incidence of metabolic dysfunction‐associated steatotic liver disease and advanced fibrosis and impact of overweight/obesity in elderly population: a nationwide cohort study
  di: Kunhee Kim, et al.
  Pubblicazione: (2024)
• Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta‐analysis of randomized controlled trials
  di: Daniel Martin Simadibrata, et al.
  Pubblicazione: (2024)
• Metabolic syndrome, its components, and gastrointestinal cancer risk: a meta‐analysis of 31 prospective cohorts and Mendelian randomization study
  di: Zhi‐Qing Zhan, et al.
  Pubblicazione: (2024)